|
KMID : 0360220180590050437
|
|
Journal of the Korean Ophthalmological Society
2018 Volume.59 No. 5 p.437 ~ p.443
|
|
|
Intravitreal Aflibercept Monotherapy for Treating Submacular Hemorrhage Secondary to Neovascular Age-related Macular Degeneration
|
|
Chae Sue-Hey
Ahn Soh-Eun
Yoon Hee-Sung
|
|
|
Abstract
|
|
|
Purpose: To evaluate the effects of intravitreal aflibercept injection in the treatment of submacular hemorrhage secondary to neovascular age-related macular degeneration (nAMD).
Methods: This retrospective, observational study included patients diagnosed with nAMD with submacular hemorrhage treated with intravitreal aflibercept monotherapy. A total of 54 eyes of 54 patients were treated with an initial series of three monthly intravitreal aflibercept injections followed by as-needed injections. At the 6 month follow-up, changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and submacular hemorrhage area (SMH) were evaluated.
Results: The mean preoperative BCVA was 0.79 ± 0.59 logMAR, which improved significantly to 0.53 ± 0.46 logMAR at 3 months and 0.48 ± 0.50 logMAR at 6 months (p ＜ 0.001, in both). The CMT significantly decreased in all eyes: preoperative, 454.4 ± 131.5 μm, to 242.6 ± 39.7 μm at 6 months. The SMH was also reduced in all eyes: preoperative, 6.4 ± 4.8 disc areas (DAs) to 0.8 ± 1.4 DAs at 6 months. Ten eyes were diagnosed with typical nAMD (18.5%) and 44 eyes were diagnosed polypoidal choroidal vasculopathy (81.5%). There was no significant difference at 6 months in the visual outcomes of the subgroups.
Conclusions: Intravitreal aflibercept monotherapy is well-tolerated as a treatment in maintaining or improving vision in patients with SMH secondary to nAMD.
|
|
|
KEYWORD
|
|
|
Aflibercept, Central macular thickness, Neovascular age-related macular degeneration, Submacular hemorrhage
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|